Phase Space Research

SanDisk

SNDK · Investment summary · as of 3 August 2026

Priced for an operating path the record does not support

Portfolio decision
No position
Price · 3 August 2026
$1,288.33
12-month target
Not determined
Expected return
-15.7%
Next decision point
Date not announced

Business type: Transition · cyclical or commodity-sensitive

The operating path required by today's price is not achievable on the evidence.

Investment view

At $1,288.33, SNDK requires a 69% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 0%.

The market's disagreement with history is not units - Q3 exabytes were flat - it is the permanence of NAND pricing, i.e. terminal margin structure.

The value rests on an exit multiple of 10.0x, a terminal operating margin of 12% and a 15.5% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.

The strongest argument against this view: NAND supply response converts shortage to glut post-FY2027 (Kioxia/SNDK BiCS adds + Samsung/SK Hynix/YMTC expansion - the FY2023 mechanism: revenue -38%, GM 7.1%).

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?The market's disagreement with history is not units - Q3 exabytes were flat - it is the permanence of NAND pricing, i.e. terminal margin structure.
What do we forecast?Revenue growth of 0% demonstrated; a terminal operating margin of 12%; an exit multiple of 10.0x.
What does Street forecast?Consensus: current-year earnings per share $66.10.
Where do we differ?On terminal margin, the difference between what the price requires and what the business has demonstrated is -34.2 percentage points.
What is it worth?Not determined — Context, not adopted: 6.0x FY27E EPS is where memory names have historically peaked (peak earnings x trough multiple); scenario-weighted 12m E[R] -15.7%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

  1. By RPO note, quarterlyRPO at or above $35bn in the FY2026 10-K or any FY2027 10-Q without commensurate revenue recognitionWhere it stands: Not determined — no current reading of this metric is on file
  2. By 10-Q MD&A ASP disclosureThe condition does not occur: Blended ASP/GB declines sequentially in any FY2027 quarter while exabyte growth < 10%Where it stands: Not determined — no current reading of this metric is on file
  3. By 10-Q income statementGross margin at or above 50% for two consecutive quarters in FY2027Where it stands: Not determined — no current reading of this metric is on file

Catalysts and falsifiers

Date or windowEventThesis confirmed ifThesis weakened or refuted if
RPO note, quarterlyContracted backlog eroding or cancellingRPO at or above $35bn in the FY2026 10-K or any FY2027 10-Q without commensurate revenue recognitionRPO below $35bn in the FY2026 10-K or any FY2027 10-Q without commensurate revenue recognition
10-Q MD&A ASP disclosurePricing regime cracking without volume offsetNeither leg of the condition opposite is met at this dateBlended ASP/GB declines sequentially in any FY2027 quarter while exabyte growth < 10%
10-Q income statementThe contracted-price floor failing to hold margin structureGross margin at or above 50% for two consecutive quarters in FY2027Gross margin below 50% for two consecutive quarters in FY2027
consensus estimates, monthlyThe post-peak repricing beginningStreet FY2027 revenue consensus revised at or above $38bn (current consensus low)Street FY2027 revenue consensus revised below $38bn (current consensus low)

Risk and sell discipline

Impairment case

NAND supply response converts shortage to glut post-FY2027 (Kioxia/SNDK BiCS adds + Samsung/SK Hynix/YMTC expansion - the FY2023 mechanism: revenue -38%, GM 7.1%). The uncontracted ~85-87% of priced-in revenue reverts; the contracted tranche and FY27 cash accumulation truncate the loss (Principle 5: the RPO raises the bear FLOOR).

Estimated probability 45%, against the 13% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $966.25 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityMetThrough-cycle ROIC ~0 and TTM ROIC is a cycle-peak artifact - reported, not scored; the cycle call is Tier-2 judgement and deliberately unscored under CYCLICAL/TRANSITION.
ValuationNot metIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetNAND supply response converts shortage to glut post-FY2027 (Kioxia/SNDK BiCS adds + Samsung/SK Hynix/YMTC expansion - the FY2023 mechanism: revenue -38%, GM 7.1%).
MomentumMet$42.50 (4 August 2025) -> $1,743.66 (2 July 2026); top of any cross-sectional universe by construction. Spot -26.1% off the high - the tape has already cracked once; ATR20 15.1%/day.
CatalystNot determinedIs there a dated event that resolves the disagreement? Not established on the evidence on file.
ConsensusMetIs the house-versus-Street disagreement identified and quantified?

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The gap between what today's price requires and what the business has demonstrated is -34.2 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: NAND supply response converts shortage to glut post-FY2027 (Kioxia/SNDK BiCS adds + Samsung/SK Hynix/YMTC expansion - the FY2023 mechanism: revenue -38%, GM 7.1%). The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $966.25, which forces an immediate review.